久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Intercept Pharma
Intercept Pharma
Intercept Pharma Intercept Pharma

美國Intercept Pharma
Intercept Pharmaceuticals是一家生物制藥公司,公司在開發用于治療慢性肝纖維化和代謝性疾病治療方法方面正處于臨床階段。  
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver disease utilizing our expertise in bile acid chemistry. Our product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions.

Our Lead Product Candidate

Our lead product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which we believe has broad liver-protective properties. We are developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to standard of care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death. We are conducting a Phase 3 clinical trial of OCA in PBC, which we call the POISE trial, that we anticipate will serve as the basis for seeking regulatory approval in the United States and Europe. We expect results from the trial to be available in the second half of 2014. OCA has received orphan drug designation in the United States and Europe for the treatment of PBC.

We own worldwide rights to OCA outside of Japan and China, where we have exclusively licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to exclusively license OCA in certain other Asian countries. Patents covering the composition of matter for OCA expire in 2022, before any patent term adjustments or patent term extensions. Our current plan is to commercialize OCA in the United States and Europe ourselves for the treatment of PBC by targeting a limited and focused group of specialist physicians.

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 国产成人精品一区二区免费视频 | 欧美性xxxxxx爱 | 制服丝袜中文字幕在线 | 在线亚洲精品国产成人二区 | 97久久精品午夜一区二区 | 在线免费一区二区 | 自拍亚洲| 国产在线观看一区二区三区 | 亚洲色图欧美 | 97热久久免费频精品99国产成人 | 亚洲人成一区二区三区 | 尤物视频黄 | 九一毛片| 日本aⅴ精品一区二区三区久久 | 亚洲国产成人久久一区www妖精 | 91社区在线观看精品 | 欧美在线观看日韩欧美在线观看 | 91专区| 国产亚洲欧美一区二区三区 | 国产网站精品 | 国产成人综合久久精品下载 | 亚洲国产成人久久综合一区 | 久久久久亚洲 | 领导边摸边吃奶边做爽在线观看 | 久久精品a一国产成人免费网站 | 国产一区在线免费观看 | 国产成人手机在线好好热 | 久久久网久久久久合久久久久 | 麻豆精品国产 | 久久91精品国产91久久小草 | 爽爽窝窝午夜精品一区二区 | 91精品国产91久久综合 | 国产日韩在线观看视频网站 | 精品一成人岛国片在线观看 | 欧美日韩国产一区 | 亚洲国产精品日韩一线满 | 欧美日韩高清 | 极品美女一区二区三区 | 国产在线视频专区 | 福利片一区二区 | 国产在线播放一区 |